Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI

Atherosclerosis

Volumn 190, Issue 1, 2007, Pages 106-113

  Corti, Roberto ^a   Osende, Julio ^a   Hutter, Randolph ^a   Viles Gonzalez, Juan F ^a   Zafar, Urooj ^a   Valdivieso, Carolina ^a   Mizsei, Gabor ^a   Fallon, John T ^a   Fuster, Valentin ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aorta; Atherosclerosis; Fenofibrate; Lipid lowering; MRI

Indexed keywords

COLLAGEN; FENOFIBRATE; PLACEBO;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA INJURY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL COUNT; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; MACROPHAGE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; RANDOMIZATION; REMISSION; SMOOTH MUSCLE FIBER;

ANIMALS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MAGNETIC RESONANCE IMAGING; MALE; PROCETOFEN; RABBITS; RENAL ARTERY;

EID: 33845452305     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.02.036     Document Type: Article

References (28)

1. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., and Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 339 (1998) 1972-1978
2. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
3. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
4. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104 (2001) 249-252
5. Lima J.A., Desai M.Y., Steen H., et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 (2004) 2336-2341
6. Nissen S.E., and for the REVERSAL Investigators. Comparison of intensive versus moderate lipid lowering on the progression of coronary atherosclerosis measured by intravascular ultrasound: a randomized controlled trial. Circulation 108 (2003) 2723
7. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
8. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
9. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
10. Fruchart J.C., Staels B., and Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res 44 (2001) 345-352
11. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
12. Fuster V., Corti R., and Badimon J.J. The Mikamo Lecture 2002: therapeutic targets for the treatment of atherothrombosis in the new millennium-clinical frontiers in atherosclerosis research. Circ J 66 (2002) 783-790
13. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
14. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.
15. Yuan C., Beach K.W., Smith Jr. L.H., and Hatsukami T.S. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation 98 (1998) 2666-2671
16. Worthley S.G., Helft G., Fuster V., et al. Serial in vivo MRI documents arterial remodeling in experimental atherosclerosis. Circulation 101 (2000) 586-589
17. McConnell M.V., Aikawa M., Maier S.E., et al. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler Thromb Vasc Biol 19 (1999) 1956-1959
18. Skinner M.P., Yuan C., Mitsumori L., et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med 1 (1995) 69-73 [see comments; published erratum appears in Nat Med 1995;1(3):272]
19. Helft G., Worthley S.G., Fuster V., et al. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. J Am Coll Cardiol 37 (2001) 1149-1154
20. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 (1998) 2433-2444
21. Corti R., Fuster V., and Badimon J.J. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 7S-14S
22. Corti R., Osende J.I., Fallon J.T., et al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 43 (2004) 464-473
23. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
24. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-3000
25. Badimon J.J., Badimon L., and Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85 (1990) 1234-1241
26. Fruchart J.C., Staels B., and Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3 (2001) 83-92
27. Spieker L.E., Sudano I., Hurlimann D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
28. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653